NYU Langone Health
Director, Gynecologic Oncology Head, Gynecologic Oncology Research Laboratory Professor, Department of Obstetrics and Gynecology Division of Gynecologic Oncology
Douglas A. Levine received his M.D. from Mount Sinai School of Medicine, completed his residency at Mount Sinai Medical Center, and fellowship at Memorial Sloan Kettering Cancer Center. In addition to his clinical practice, Dr. Levine is the Head of the Gynecology Research Laboratory, where he studies cancer prevention, precision medicine, and rare tumors with unmet needs. He serves as the translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. He discovered universal mutations in SMARCA4 that drive small cell carcinoma of the ovary, hypercalcemic type. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women’s health. Dr. Levine has been very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He serves as co-chair of the ovarian, endometrial, and uterine carcinosarcoma disease working groups. He is a member of the Scientific Advisory Committee of the Ovarian Cancer Research Fund, the Clearity Foundation, and the Honorable Tina Brozman Foundation. He has authored or co-authored more than 200 peer-reviewed articles and two textbooks. Dr. Levine has received funding from the National Cancer Institute, the Department of Defense, Stand Up 2 Cancer, and the Gynecologic Oncology Group. He has been awarded the American Congress of Obstetricians and Gynecologists Mentor Award, served as co-chair of the American Association for Cancer Research Special Conferences on Ovarian Cancer, received the 2013 Foundation for Women’s Cancer Excellence in Ovarian Cancer Research Prize, is the Assistant Dean of the Department of Defense Ovarian Cancer Academy, and was recently appointed as translational science co-chair of the NRG Oncology Corpus Committee.
The Rivkin Center strives for excellence in our scientific programming. Our Scientific Advisory board guides the work we do and helps shape our vision for the future of ovarian cancer research. The Board is led by Dr. Mary L. (Nora) Disis, MD, our Scientific and Medical Director, and consists of nationally recognized experts in ovarian cancer research.